Summary of the Interim Report for Q2 2021
Consolidated group evenue | 0 | ||
Consolidated group loss before depreciation | -12,544 TSEK | ||
Consolidated group loss before net financials | -12,544 TSEK | ||
Consolidated net result | -12,555 TSEK | ||
Consolidated earnings per share (EPS) |
- |
Highlights during Q2 2021
- On
June 27, 2021 ,Biosergen announced that theUnited States Food and Drug Administration (the "FDA") has granted BSG005, the Company's groundbreaking antifungal drug of the polyene macrolide class, Orphan Drug status inthe United States . -
On
June 23, 2021 ,Biosergen announced that the Company has been approved for listing on Nasdaq First North Growth Market. The first day of trading will beJune 24, 2021 ., -
On
June 8 ,Biosergen confirmed that its IPO had been successfully executed, raising a gross amount of approximatelySEK 50 million . In the event that the investor warrants allocated to the new shares issued are exercised in full during the period fromMay 30, 2022 throughJune 10, 2022 , the company may receive additional net proceeds from the offering of up toSEK 100 million . -
On
May 18, 2021 , the Board of Directors ofBiosergen decided to conduct a rights issue of shares supported by an authorization granted at the General Meeting. The rights issue comprised of up to 5,000,000 offer units, each consisting of one new share at a subscription price ofSEK 10 and a warrant with the exercise price ofSEK 20 to be exercised during the period fromMay 30, 2022 throughJune 10, 2022 . -
On
May 4, 2021 , the board of directors resolved on an issue by way of set-off to Östersjöstiftelsen in order to improve the Company's financial position. The Company's share capital was increased withSEK 19,923,575 through an issue of 796,943 shares. -
In April, the Company acquired all the shares in Biosergen AS through an issue in kind where the Company's share capital was increased with
SEK 1,115,241.6 through an issue of 22,304,832 shares.
HIGHLIGHTS AFTER THE PERIOD
- On
August 24, 2021 ,Biosergen AB announced that it has received positive feed back from the Australian regulatory authorities on the application to initiate a phase I study inAustralia of the Company's proprietary antifungal drug candidate BSG005. With the approval,Biosergen is ready to conduct its First in Man clinical trial with BSG005.
The Financial report can be found on our website: https://biosergen.net/investors/filings
For further information about
Dr.
Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net
Certified Adviser
Telefon: +46 8 463 8000
E-mail: certifiedadvisor@penser.se
This information is such information that
ABOUT
https://news.cision.com/biosergen-ab/r/biosergen-publishes-interim-report-for-the-second-quarter-2021,c3406501
https://mb.cision.com/Main/20568/3406501/1461736.pdf
https://mb.cision.com/Public/20568/3406501/aecdf221a957294e.pdf
(c) 2021 Cision. All rights reserved., source